The Myrovlytis Trust is driven by its vision of a world free from rare genetic disorders. More than 6000 rare diseases have been described, of which 80% are considered to be genetic [Eurordis: What is a rare disease?]. We passionately believe that no one should be disadvantaged because they have inherited a rare genetic disorder.

Since it was founded in 2007 the Myrovlytis Trust has been promoting research into Birt-Hogg-Dube syndrome (BHD), an inherited genetic condition linked to benign skin growths, collapsed lung and kidney cancers. The Myrovlytis Trust is now expanding its work into related rare genetic kidney disorders.

There is an ongoing unprecedented innovation in medicine, including increased understanding of the human genome and advances in personalised therapies. We are passionate about maximising this unique opportunity to develop treatments for rare genetic disorders.

   Read about our Mission and Priorities.